N/A N=31 A Biomechanical Exercise Program for Knee OA
Osteoarthritis, Knee
Primary: Change in Lower Extremity Function — 10.6; 7.6; -6.4 Change in scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=5 Intranasal Delivery of Testosterone and Its Effect on Doping Markers
Abuse of Anabolic Steroids
Primary: Steroid Levels in Urine Steroid Profile — 69.5773456; 138.0291641; 163.117081; 107.7160658 ng/mL
Phase 2 N=22 Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
Melanoma
Primary: Safety Measurement - Percentage of Patients Experiencing Serious Adverse Events (SAEs) in the First 4 Months of Treatment. — 9 Participants
N/A N=68 Comparison of Oral Hygiene & Root Resorption During Orthodontic Treatment
Orthodontic Pathological Resorption of External Root · Complication of Personal Oral Hygiene
Primary: Plaque Index — 0.5; 0.7; 0.7; 0.8 Plaque Index (PI)
Phase 2 N=12 A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Carcinoma · Stage IV Renal Cell Cancer
Primary: Objective Response Rate (PR + CR) Using RECIST — 0 participants
Phase 1 N=50 A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 1; 4; 1; 3 participants
N/A N=191 A Randomized Controlled Trial of Lung Ultrasound Compared to Chest X-ray for Diagnosing Pneumonia in the Emergency Department
Pneumonia
Primary: Percentage of Participants For Whom CXR Was Not Needed to Diagnose Pneumonia — 38.8; 0 percentage of participants
Phase 4 N=114 Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
Type 2 Diabetes · Renal Insufficiency
Primary: Average Blood Glucose Over 6 Days — 174; 174.5 milligrams per deciliter — p=.958
Phase 4 N=51 B-cell Immunity to Influenza (SLVP017)- Year 1, 2009
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 6; 24; 21 Participants
Phase 1 N=35 Florbetapir Calibration to the Centiloid Scale
Alzheimer's Disease
Primary: Florbetapir SUVr Conversion to Centiloid Units — 82.44; 50.75; 81.19; 14.93 centiloid
Phase 4 N=50 Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
Genital Herpes
Primary: Frequency of HSV-2 Total Shedding From the Genital Tract as Measured by PCR, Calculated Using a Per-day Shedding Rate in Participants Treated With High-dose Valacyclovir…
N/A N=11 Acid-Base Composition With Use of hemoDialysates
End Stage Renal Disease
Primary: Peridialytic Arterialized Blood Bicarbonate Concentrations — 25.7; 27.1; 27.2; 27.4 mEq/l — p=<0.0001
N/A N=183 Integrated vs Sequential Treatment for PTSD and Addiction
PTSD · Substance Addiction
Primary: PTSD Symptoms — 55.5; 54.1 units on a scale
Phase 4 N=20 T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 20 Participants
Phase 3 N=198 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Brain Tumors · Metastatic Disease
Primary: Memory as Quantified by HVLT-immediate Recall — 22.5; 22.2 units on a scale — p=.62